FDA Foreign Inspections Capture Monograph, GMP Violations
This article was originally published in The Tan Sheet
Executive Summary
An August letter to Jabones Pardo follows a number of FDA warnings to international firms that market products in the cosmetics and personal care space and violate U.S. drug regulations. Warnings to OTC product firms outside the U.S. over the past two years reflect the higher priority FDA has assigned to inspecting international firms.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: